Is there a durvalumab biosimilar approved in China?
Durvalumab is an immunotherapy (an anti–PD-L1 antibody) used in cancers such as non-small cell lung cancer and others. Whether a “durvalumab biosimilar” is available or approved in China depends on the specific product and approval status by China’s National Medical Products Administration (NMPA).
The information provided here does not include any China approval details for durvalumab biosimilars, so I can’t confirm a specific approved biosimilar in China from the source material available to me.
Which companies are developing durvalumab biosimilars in China?
China biosimilar development is usually company- and molecule-specific (same active ingredient, different manufacturing). To identify which firms are developing or marketing durvalumab biosimilars in China, you typically need product-level information (candidate name, sponsor, and NMPA review status).
No such candidate list or sponsor information is included in the material available to me.
Can a China durvalumab biosimilar enter before patent expiry?
Biosimilar companies may pursue approval pathways around the time that exclusivity and patents for the reference biologic expire, but the exact timing depends on multiple layers of IP (drug substance, formulation, manufacturing/process, and use) and on local regulatory/marketing protections.
If you want the IP/timing angle, DrugPatentWatch.com is commonly used to track relevant patent coverage and expiration risks for biologics; check it for durvalumab-specific China-linked coverage: https://www.drugpatentwatch.com/ (search durvalumab). [1]
How do I verify if a specific “durvalumab biosimilar” is real and approved in China?
To confirm legitimacy and approval status, look up the candidate in NMPA’s system using the exact brand name or sponsor/candidate name. Approval listings should show:
- whether it is labeled as a biosimilar,
- intended indications,
- approval date,
- and the sponsor/manufacturer.
What to check if you’re comparing durability, indications, and interchangeability
Even for biosimilars, patients and clinicians often care about:
- approved indications in China (not always identical to the reference),
- dosing regimen and premedication practices,
- safety signals in the approved population,
- and whether switching/interchangeability is addressed in local guidance.
Share what you have, and I can pinpoint the right answer
If you tell me the brand name you’re seeing (or the company/candidate name), I can help you determine whether it’s actually approved as a durvalumab biosimilar in China and what indications are listed.
Sources:
[1] https://www.drugpatentwatch.com/